Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ONCY's Cash to Debt is ranked higher than
96% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ONCY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONCY' s 10-Year Cash to Debt Range
Min: 45.91   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONCY's Interest Coverage is ranked higher than
96% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONCY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.53
M-Score: -3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -92.34
ONCY's ROE (%) is ranked lower than
57% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -61.96 vs. ONCY: -92.34 )
Ranked among companies with meaningful ROE (%) only.
ONCY' s 10-Year ROE (%) Range
Min: -164.19   Max: -26.92
Current: -92.34

-164.19
-26.92
ROA (%) -75.98
ONCY's ROA (%) is ranked lower than
64% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -39.06 vs. ONCY: -75.98 )
Ranked among companies with meaningful ROA (%) only.
ONCY' s 10-Year ROA (%) Range
Min: -125.21   Max: -25.07
Current: -75.98

-125.21
-25.07
ROC (Joel Greenblatt) (%) -3313.88
ONCY's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1309.62 vs. ONCY: -3313.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15749.15   Max: -250.97
Current: -3313.88

-15749.15
-250.97
EBITDA Growth (3Y)(%) -19.30
ONCY's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 1055 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: -19.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ONCY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -19.3   Max: 42.6
Current: -19.3

-19.3
42.6
EPS Growth (3Y)(%) -20.00
ONCY's EPS Growth (3Y)(%) is ranked higher than
74% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: -20.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ONCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -20   Max: 21.9
Current: -20

-20
21.9
» ONCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ONCY Guru Trades in Q4 2013

First Eagle Investment 427,200 sh (unchged)
Jim Simons 19,200 sh (-39.05%)
» More
Q1 2014

ONCY Guru Trades in Q1 2014

Jim Simons 23,600 sh (+22.92%)
First Eagle Investment 427,200 sh (unchged)
» More
Q2 2014

ONCY Guru Trades in Q2 2014

Jim Simons 36,000 sh (+52.54%)
First Eagle Investment 188,600 sh (-55.85%)
» More
Q3 2014

ONCY Guru Trades in Q3 2014

Jim Simons Sold Out
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.89
ONCY's Forward P/E is ranked higher than
94% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: 10.89 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.30
ONCY's P/B is ranked higher than
64% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: 3.30 )
Ranked among companies with meaningful P/B only.
ONCY' s 10-Year P/B Range
Min: 1.25   Max: 18.75
Current: 3.3

1.25
18.75
Current Ratio 7.24
ONCY's Current Ratio is ranked higher than
73% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.70 vs. ONCY: 7.24 )
Ranked among companies with meaningful Current Ratio only.
ONCY' s 10-Year Current Ratio Range
Min: 2.21   Max: 142.02
Current: 7.24

2.21
142.02
Quick Ratio 7.24
ONCY's Quick Ratio is ranked higher than
74% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ONCY: 7.24 )
Ranked among companies with meaningful Quick Ratio only.
ONCY' s 10-Year Quick Ratio Range
Min: 2.21   Max: 142.02
Current: 7.24

2.21
142.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.40
ONCY's Price/Net Cash is ranked higher than
85% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: 6.40 )
Ranked among companies with meaningful Price/Net Cash only.
ONCY' s 10-Year Price/Net Cash Range
Min: 2.63   Max: 24.08
Current: 6.4

2.63
24.08
Price/Net Current Asset Value 6.40
ONCY's Price/Net Current Asset Value is ranked higher than
85% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: 6.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONCY' s 10-Year Price/Net Current Asset Value Range
Min: 2.56   Max: 22.36
Current: 6.4

2.56
22.36
Price/Tangible Book 5.80
ONCY's Price/Tangible Book is ranked higher than
68% of the 1039 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: 5.80 )
Ranked among companies with meaningful Price/Tangible Book only.
ONCY' s 10-Year Price/Tangible Book Range
Min: 2.06   Max: 22.36
Current: 5.8

2.06
22.36
Earnings Yield (Greenblatt) -26.60
ONCY's Earnings Yield (Greenblatt) is ranked lower than
81% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONCY: -26.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ONCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -26.6   Max: 2116.4
Current: -26.6

-26.6
2116.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ONC.Canada, ONY.Germany,
Oncolytics Biotech Inc was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. The Company is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The Company focused on the development of oncolytic viruses for use as cancer therapeutics. Its product, REOLYSIN, a proprietary formulation of the human reovirus, is in late stage (Phase III) clinical testing in head and neck cancers.
» More Articles for ONCY

Headlines

Articles On GuruFocus.com

More From Other Websites
Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors May 19 2015
Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
Oncolytics Biotech® Inc. Announces 2015 First Quarter Results May 07 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric... May 06 2015
Oncolytics' Reolysin Gets Another Orphan Drug Status in EU - Analyst Blog May 01 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer Apr 29 2015
Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price... Apr 28 2015
Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog Apr 20 2015
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual... Apr 20 2015
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual... Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK